May 2022 FDA Recall Losartan Potassium And Hydrochlorothiazide by Direct Rx
D-0971-2022 - CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

This Class II drug recall was voluntarily initiated by Direct Rx on May 5, 2022 for the product Losartan Potassium And Hydrochlorothiazide. The FDA reported the reason for recall as cgmp deviations- azido impurity levels observed to be above acceptable limits. The product was distributed in AL, GA, FL, LA and the recall is currently terminated.

Recall Number: D-0971-2022

Reason for Recall
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Initiated
05-05-2022
Reported
06-08-2022
Quantity
81 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Losartan Pot./HCTZ 100/12.5 mg Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Mfg For: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 a) 30 Tabs NDC 72189-167-30; b) 90 Tabs NDC 72189-167-90

Batch or Lot Expiration Information

Lot# a) 30-count bottles- Lot: 11MY2103 Exp. 11/30/22 Lot: 05JA2106 Exp. 6/30/22 b) 90-count bottles- Lot: 20MY2115 Exp. 11/30/22 Lot: 22JU2118 Exp. 12/31/22 Lot: 29JY2113 Exp. 12/31/22 Lot: 13SE2113 Exp. 2/28/23 Lot: 05JA2106 Exp. 6/30/22